Fezakinumab | Interleukin Related interleukin-related.com

Product Name :
Fezakinumab

Search keywords :
Fezakinumab

drugId :
null

Target Vo:
Interleukin-22

Target Vo Short Name :
IL22

Moa_Name:
Interleukin-22 inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Pfizer Inc

Active Company_Name :

Active Indication_Name:

In Active Indication_Name:
Arthritis, Rheumatoid

Termination Status :
Phase 2 Clinical

China Termination Status :

Highest Status:
Pending

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
FABP4 Antibody
Phospho-EGFR (Tyr1173) Antibody
Cyclin B2 Antibody: Cyclin B2 Antibody is an unconjugated, approximately 45 kDa, anti-Cyclin B2 monoclonal antibody. Cyclin B2 Antibody can be used for: WB, IHC-P, ICC/IF, IP expriments in human, mouse, rat background without labeling.

Author: Interleukin Related

Related Posts